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Abstract
Background: Generic quality of life (QoL) instruments provide important measures of self-reported wellbeing that
can be compared across healthy and clinical populations. The aim of this analysis is to validate the ten-item QoL
instrument “QOL10”, as well as to confirm the validity of the embedded “QOL5” questionnaire and single-item
“QOL1” in measuring overall QoL among adults in a substance use disorder treatment study.
Methods: We used exploratory factor analysis and measured internal and convergent validity of the QOL10 against
the gold standard measure of the WHOQOL-BREF, in a subsample of 107 participants in a substance use disorder
treatment study.
Results: The QOL10 displayed internal and convergent validity to the gold standard measure. Factor analysis
revealed a two-factor structure that can be interpreted as “social QoL”, containing items about relationships and
social functioning, and “global QoL”, comprised of items about health, working ability, self-evaluation, and an overall
QoL estimation.
Conclusions: The QOL10 provides clinically useful and valid measures of social-related QoL and global QoL via two
subscales. Interestingly, the QOL10’s social QoL measure, from the current sample, had little relationship to the
analyzed groups previously reported to have differential global QoL: social QoL appears to be not only conceptually
distinct from global QoL, but also to be less influenced by typical substance- and treatment-specific factors.
Background
Quality of life is one of the most common patient-
reported outcomes, as it utilizes patients’ perceptions
and expectations to capture the lived experiences of dis-
ease and treatment [1]. In marginalized patient groups
such as persons with a substance use disorder (SUD),
using subjective information from patients instead of
clinicians to plan and evaluate treatment modalities is
not only empowering, but also an effective way of
discovering the effects of disease status and treatment on
a wide range of life areas [2]. Subjectivity is a prerequisite
to a good QoL instrument, as subjective responses allow
participants to evaluate “their life satisfaction, taking into
account the balance between positive and negative as it
was relevant to their individual experience rather than the
researcher deciding” (p.8) [2].
Multidimensional QoL measures such as the World
Health Organization’s WHOQOL-BREF include mental
health, physical mental, social, and environmental
dimensions [1, 3]. Research with the SUD population,
however, often focuses exclusively on health-related QoL
[4, 5]. This is despite qualitative findings that patients
conceptualize QoL to be more about social inclusion
and support than health [2, 6] and that SUD patients
report worse social functioning than other chronic
disease groups [7].
Validating a QoL instrument among the SUD popula-
tion exposes the problem of a paucity of known groups,
that is, few subgroups which consistently report differen-
tial QoL and can therefore be used to test the sensitivity
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of the instrument. While persons with a SUD report
markedly lower QoL than those without, including those
with other chronic diseases [8], few QoL-specific indica-
tors among the SUD population have been established.
Reviews have shown psychological distress to be the
most consistent predictor of poor QoL, while substance
use severity, primary substance type, age, and gender
have unclear relationships to QoL [5, 9]. While less sys-
tematically published, QoL has been reported to be
higher among treatment completers versus drop-outs or
those only beginning treatment [10, 11], the physically
active compared to inactive [12], and those who report
social activity versus isolation [13].
Generic as opposed to disease-specific QoL instru-
ments are particularly important because they utilize a
wellness paradigm rather than a pathology paradigm,
and correspond to a treatment focus of improved overall
functioning and satisfaction with functioning rather than
simply symptom reduction [14]. Because they are not
limited to disease-related functioning, the estimations of
QoL they produce can be compared across healthy and
clinical populations and interventions.
The validation of an additional QoL instrument pro-
vides researchers with a different mechanism – and
more opportunities – to explore the differences in QoL
and ascertain the influence of new factors. The QOL10
is of interest because it can be implemented with low
administrative burden, due to its short length and simple
scoring instructions. We wished to validate the QOL10
among the SUD population in Norway with an analytic
strategy that has been previously used to validate
patient-reported outcome measures [15, 16]. Secondly
we wanted to confirm the validity of the embedded
QOL5 questionnaire and single-item QOL1.
Methods
Participants
Data for this validation study were contributed by a sub-
sample of participants in the Norwegian Cohort of
Patients in Opioid Maintenance Treatment (NorComt),
recently described in Skjærvø et al. [17]. The NorComt
study is a naturalistic, longitudinal study of persons in
opioid maintenance treatment (OMT) aimed at explor-
ing factors that impact treatment retention and quality
of life. 549 individuals beginning either OMT or
medication-free inpatient treatment in 21 participating
facilities were recruited from 2012 to 2015. The only
inclusion criterion into this study was recent admittance
into a substance use disorder treatment facility, regard-
less of primary substance type(s).
Data in this paper came from 107 consecutive follow-up
interviews with participants who had begun treatment,
and entered the study, one year earlier. Participants did
not have to be in any formal treatment at the time of
the follow-up interviews. Participants’ sociodemographic,
substance-related, and health variables are presented in
Table 1, and data collection is further described in
Procedure.
Measures
Quality of life measures
The QOL10 is a ten-item general QoL instrument devel-
oped using Ventegodt et al’s clinical experience with the
QOL5, an earlier, shorter tool they developed [18, 19].
Table 1 Sample descriptives (N = 107)
n or mean % or SD
Demographics
Age 34.3 9.6
Women 36 33.6 %
Single 78 77.2 %
Primary education or less 61 57.0 %




None 20 18.7 %
Methadone/buprenorphine 32 29.9 %
Cannabis 14 13.1 %
Alcohol 13 12.1 %
Amphetamines 9 8.4 %
Heroin/opium 5 4.7 %
Benzodiazepines 5 4.6 %
Ecstasy, LSD, stimulants, cocaine, i
nhalants, or other addictive substances
0 0 %
Other not listed 9 8.6 %
Polysubstance user 49 49.0 %
Injected within past four weeks 25 25.5 %
Current SUD treatment
None 20 19.9 %
Outpatient with OMT 46 43.8 %
Outpatient without OMT 15 14.0 %
Inpatient with OMT 14 13.1 %
Any treatment attrition, past year 35 35.0 %
Health variables
Additional chronic disease 71 66.4 %
Clinical anxiety symptoms 61 57.0 %
Clinical depression symptoms 60 56.1 %
Received psychiatric services, past year 55 50.9 %
Physically inactive 38 35.5 %
Demographic, substance-related, and health variables of the sample
SUD substance use disorder
OMT Opioid maintenance treatment
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The QOL10 has not yet been validated, but was built
from the validated five-question QOL5 (questions 1–5)
and the validated single-item measure of QoL called the
QOL1 (question 10). An example item is question 9,
“how is your working ability at the moment?” Responses
were given on a 1–5 Likert scale of “very good”, “good”,
“neither good nor poor”, “poor”, and “very poor” (items
are listed in Table 2).
The gold standard measurement selected was the
WHOQOL-BREF, a widely used and validated 26-item
self-report tool suggested to be the most appropriate
multidimensional tool for use among the SUD popu-
lation [14, 20]. The WHOQOL-BREF produces four
domain scores – physical health QoL via seven items,
psychological health QoL via six items, social relation-
ships QoL via three items, and environment QoL via
eight items – as well as one single-item measure of over-
all QoL mirroring the QOL1 and one of general health.
The WHOQOL-BREF uses a nearly identical Likert scale
as the QOL10 but with higher numbers indicating posi-
tive responses. We present the four domain scores as
well as the single item measuring overall QoL; the
second single-item question measuring self-reported
health was not considered relevant to this analysis and is
not presented.
Demographic, health, and substance-related measures
Substance use and severity indicators were measured
using excerpts from the EuropASI [21], a validated version
of the Addiction Severity Index adapted for European use.
The Hopkins Symptoms Checklist-25 measured symptom
levels of clinical anxiety and depression, using a cut-off of
1.0 on the anxiety and depression scales [22]. Missing
items in the HSCL-25 were replaced by the appropriate
subscale mean. Dichotomized health variables defining
groups previously reported to have differential QoL were
self-reports of additional chronic somatic disease status
(with or without a chronic disease, e.g., coronary heart
disease, diabetes, or hepatitis C), mental health status
(with or without symptoms of clinical anxiety, and with or
without symptoms of clinical depression), physical inactiv-
ity (those who were or were not inactive), and psychiatric
services utilization (those who received any psychiatric
services in the past year versus those who did not)
[23–26]. Sociodemographic variables included civil status
Table 2 Descriptive statistics of the “QOL10”, “QOL5”, and “QOL1”
Responses [n (%)]
N Very poor Poor Neither good nor poor Good Very good Mean (s.e.m.) Skewness Kurtosis
Items
1. How do you consider your physical
health at the moment? (QOL5)
107 7 (6.5) 15 (14.0) 29 (27.1) 43 (39.3) 14 (13.1) 0.58 (.02) -.54 -.25
2. How do you consider your mental
health at the moment? (QOL5)
107 7 (6.5) 14 (13.1) 32 (29.9) 41 (37.4) 14 (13.1) 0.58 (.02) -.57 -.15
3. How do you feel about yourself at
the moment? (QOL5)
105 4 (3.7) 11 (10.3) 38 (36.2) 42 (40.0) 10 (9.3) 0.58 (.02) -.54 .20
4. How are your relationships with your
friends at the moment? (QOL5)
102 4 (3.9) 12 (11.8) 17 (15.9) 57 (55.9) 12 (11.8) 0.63 (.02) −1.15 1.27
5. How is your relationship with your
partner at the moment? (QOL5)
43 1 (2.3) 4 (9.3) 5 (11.6) 14 (32.6) 19 (44.2) 0.66 (.02) -.48 -.13
6. How do you consider your ability to
love at the moment?
107 4 (3.7) 6 (5.6) 13 (12.1) 38 (35.5) 46 (43.0) 0.72 (.02) −1.25 .1.13
7. How do you consider your sexual
functioning at the moment?
102 11 (10.8) 11 (10.8) 18 (17.6) 34 (33.3) 28 (26.2) 0.61 (.03) -.68 -.59
8. How do you consider your social
functioning at the moment?
106 5 (4.7) 13 (12.1) 31 (29.0) 35 (32.7) 22 (20.6) 0.61 (.02) -.44 -.42
9. How is your working ability at
the moment?
104 13 (12.5) 15 (14.0) 23 (21.5) 34 (32.7) 19 (18.3) 0.56 (.02) -.40 -.85
10. How would you assess your
quality of your life now? (QOL1)
107 5 (4.7) 25 (23.4) 36 (33.6) 31 (29.0) 10 (9.3) 0.53 (.02) -.05 -.62
Scores
QOL10 103 0.59 (0.01)
QOL5 104 0.60 (0.01)
QOL1 107 0.53 (0.02)
Descriptive statistics (item responses and scale statistics) of the three quality of life tools, “QOL10”, “QOL5”, and “QOL1”
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(“single” or “married/partnered”), unemployment, and
educational attainment of primary school or less.
Procedure
The NorComt study collected data via structured, face-
to-face interviews conducted by trained interviewers,
once when participants entered treatment (baseline) and
again one year later (follow-up). Interviews typically
lasted 1.5 h. The QOL10 and embedded QOL5 and
QOL1 were collected at baseline and follow-up. In order
to provide us with QoL data from a validated tool that
we could use to determine how best to analyze the simi-
lar, longitudinal data from the QOL10 in future analyses,
the gold standard WHOQOL-BREF was administered to
a sub-sample of 107 consecutive follow-up interviews.
Participants provided written informed consent to the
NorComt study, and the Norwegian Regional Ethics
Committee approved the project and this subanalysis.
Statistical analysis
Methodological testing
The COSMIN checklist for patient-reported outcome in-
struments provided a helpful framework for methodo-
logical testing [27]. Reliability, or whether a measurement
is free from measurement error, was assessed through
internal consistency and measurement error. Validity, the
degree to which a questionnaire measures the construct it
intends to measure, was assessed through measuring face
validity, convergent/discriminant validity to the gold
standard, and responsiveness to known groups.
Descriptive statistics were calculated to describe the
sample, the QOL10 items’ characteristics, scores for the
QOL10, QOL5, and QOL1, and the WHOQOL-BREF
domain scores and single-item score. WHOQOL-BREF
raw domain scores were transformed according to the
WHO Group’s guidelines [3], yielding four domain
scores on a 0–100 scale comparable to other World
Health Organization QoL tools. Raw item scores from
the QOL10, QOL5, and QOL1 were converted into a
0.1-0.9 scale where 0.1 corresponded to the worst rating
and 0.9 to the best. Mean scores were calculated for
health, ability, and self-assessed aspects of QoL, and
composite scores were calculated as the mean of these
three aspects for the QOL10 and QOL5 [19]. The ques-
tion asking about one’s relationship to a partner was ex-
cluded in calculations for those who did not answer this
question, as per the developers, as a lack of a “not ap-
plicable” option led to 63 missing answers for this item.
To determine whether the QOL10 measured multiple
domains of QoL that could be validated against the
domains of the WHOQOL-BREF, we used exploratory
factor analysis to explore a possible factor structure. The
data were tested to ensure they met the requirements
for a factor analysis (FA) using the Kaiser-Meyer-Olkin
measure of Sampling Adequacy and Bartlett’s test of
sphericity [28]. An oblique rotation was chosen for the
FA as we anticipated that the underlying factors would
be related. A generalized least squares estimation pro-
cedure was used, as it is considered the most appropriate
for our sample size of just over 100 [29, 30]. Goodness
of fit was determined by χ2, wherein a non-significant χ2
suggests the factor model adequately describes the
relationships among the variables [31]. The number of
factors was determined using the FA and the number of
factors to retain was determined using a scree plot and
eigenvectors greater than 1. Ten item means and stand-
ard error were calculated for item analysis. Factor load-
ings of 0.4 or above were considered relevant [32], and
any items with high loadings on multiple factors were
assigned to their highest loaded factor. Missing data was
excluded pairwise due to the large missing amount for
the “partner” question.
Using the items determined relevant to each factor,
subscales for the QOL10’s factors were derived using the
same methodology as the WHOQOL-BREF’s domain
scores. Missing data was also treated according to the
WHO Group’s guidelines: a subscale was not calculated
if any item was missing, as each factor contained less
than six items (with the exception of the question asking
about partners; the social subscale was calculated based
on the four remaining questions for participants who
did not answer the partner question). Cronbach’s α was
calculated to evaluate the internal consistency of the
subscales as well as the entire QOL5; α is not a useful
test of multidimensional reliability and therefore not cal-
culated for the entire QOL10.
Convergent/discriminant validity was tested through
measuring Pearson’s product moment correlation (r) be-
tween composite QOL10, QOL5, and QOL1 scores,
QOL10 subscales, and WHOQOL-BREF domains hypoth-
esized to measure equivalent constructs, and through
measuring the point-biserial correlation (rpbc) between
known groups and the various QoL tools. We hypothe-
sized that each score and subscale from the QOL10 would
display convergent validity with the WHOQOL-BREF do-
mains, and that the QOL10 scores would be able to dis-
criminate between the known groups [15]. A p-value of
0.05 was used to determine statistical significance. Finally,
a brief discussion of face validity explored the appropriate
subjectivity of the QOL10’s items. SPSS version 22 was
used for all statistics.
Results
QOL10 item statistics and composite score, and QOL5
and QOL1 scores
Responses to most items in the QOL10 skewed towards
“good”, with this response being the most common for
seven items (between 32.7 % and 55.6 %). Responses
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were higher for the “love” and “partner” items (most an-
swered “very good”), and lower for the “overall QoL”
item (most answered “neither good nor poor”).
Most items were missing very few answers – between
0 and 5 – with the exception of the “partner” question,
which was not applicable for 63 participants. The mean
composite score for the QOL10 was 0.59 (on a 0.1–0.9
scale), 0.60 for the QOL5, and 0.53 for the QOL1. De-
tails are presented in Table 2.
WHOQOL-BREF domain scores and single-item score
The lowest-reported domain was physical health QoL
(mean of 44.9, on a scale of 0–100), while the highest
was social relationships QoL (62.3). Scores for psycho-
logical health QoL (54.6) and environment QoL (57.3)
scores fell in-between. Most participants (36.4 %)
responded “good” to the single item rating overall QoL,
and the next largest proportion responded “neither good
nor poor” (34.6 %), followed by “very good” (15.0 %),
“poor” (13.1 %), and “very poor” (0.9 %). Cronbach’s
alpha was acceptable for the physical health domain
(.763), psychological health domain (.792), and environ-
ment domain (.762), but was somewhat lower for the
social relationships domain (.541).
Construct validity
Exploratory factor analysis
The Kaiser-Meyer-Olkin measure of Sampling Adequacy
(KMO = 0.779) and Bartlett’s test of sphericity [χ2 (45) =
133.52, P < 0.001] indicated that the data were adequate
for conducting a FA. The FA extracted two significant
factors which together explained 56.0 % of the total vari-
ance. Eigenvalues were 3.57 and 1.20 before oblique ro-
tation, and 2.85 and 2.72 after rotation. Factor loadings
are presented in Table 3. The first factor of the two
retained factors is interpreted as “social QoL”, and con-
tains five items on one’s social functioning, ability to
love, relationship to friends, sexual functioning, and
relationship to partner. The second retained factor is
interpreted as “global QoL” and includes five items on
mental health, physical health, a global assessment of
QoL (the latter question comprising the QOL1), working
ability, and how one feels about oneself. The factors
were moderately associated with one another (r = 0.339).
Three out of ten items were associated with both factors,
which is an overlap expected between two correlated
factors. According to the χ2 goodness-of-fit test, the
model provided a suitable fit.
Reliability was acceptable for both subscales of the
QOL10 and for the QOL5 composite scale. Table 4 dis-
plays Cronbach’s α for each factor extracted: 0.814 for
the “social QoL” factor and 0.771 for the “overall QoL”
factor. Cronbach’s α for the QOL5 scale was 0.718.
Association of QoL scores with WHOQOL-BREF scores and
known groups
Table 5 shows how each QOL10 composite score and
subscale correlates with the gold measure standard and
known groups. As hypothesized, the QOL10’s single-
item measure of global QoL, the QOL1, correlated
strongly with the WHOQOL-BREF’s single-item meas-
ure (r = 0.671, p < 0.001), as did the QOL5 and QOL10.
The QOL10, QOL5, and QOL1 were also strongly corre-
lated to each domain of the WHOQOL-BREF (between
r = 0.382 and r = 0.768, p < 0.001). Our hypotheses about
subscale correlations to the gold standard were also met.
The highest correlation between the “social QoL” sub-
scale was with the social relationships domain (r = 0.680,
p < 0.001), suggesting appropriate convergent validity
with this domain.
Our hypotheses regarding the QOL10’s ability to
discriminate between groups previously reported to have
differential global QoL, were partly confirmed. QOL10,
QOL5, and QOL1 scores were negatively related with
exhibiting symptoms of clinical anxiety, clinical depres-
sion, and being physically inactive, but did not distinguish
between the remaining two known groups, namely, psy-
chiatric services utilization and additional chronic somatic
disease. The global subscale’s correlations with known
groups followed the same pattern as among the QOL10,






How do you consider your social
functioning at the moment?
0.829
How do you consider your ability
to love at the moment?
0.664
How are your relationships with
your friends at the moment?
0.599
How do you consider your sexual
functioning at the moment?
0.577
How is your relationship with your
partner at the moment?
0.541
How do you consider your mental
health at the moment?
0.421 0.739
How would you assess your quality
of your life now?
0.502 0.714
How do you consider your physical
health at the moment?
0.711
How do you feel about yourself at
the moment?
0.497 0.608
How is your working ability at the
moment?
0.570
Goodness of fit: χ2 = 17.327, d.f. = 26,
p = 0.899
QoL: quality of life
Factor structure and loadings of the “QOL10” after exploratory factor analysis
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QOL5, and QOL1. The social subscale correlated
only with those exhibiting symptoms of clinical anxiety
(r = −0.251, p < 0.05).
Face validity
Each item in the QOL10 elicits self-evaluations of vari-
ous aspects of QoL (e.g., item 4, “how are your relation-
ships with your friends?”) rather than attempting to
measure their quality objectively (e.g., “to what extent
can you confide in your friends?”) or quantifying them
(“how many friends do you have?”). The QOL10’s word-
ing allows the respondent to consider, in this example,
whichever functions s/he expects to be performed by
friends, to evaluate these relationships based on global
friendship expectations or on individual expectations, to
compare them to past performance, and so on [33].
Discussion
In this paper, we validated the “QOL10” for the first time
against the gold standard of the WHOQOL-BREF, in a
sample of 107 participants in a substance use disorder
treatment study. We also confirmed the validity of
the embedded “QOL5” questionnaire and single-item
“QOL1” in measuring global quality of life (QoL). The
QOL10 provides short, clinically useful measures of social
QoL and global QoL via two subscales. The social subscale
is of particular utility, as social QoL is rarely explored
among this population but appears to be conceptually
distinct from global QoL. Our findings also suggest that
social QoL is less influenced by typically-measured health,
substance and treatment-specific factors. Social QoL may
“respond” differently than global QoL to typical treatment
practices, pointing towards the importance of interven-
tions targeted specifically at the social lives of the SUD
population. The first step in designing such interventions
is introducing patients’ social lives as priorities in the
clinical encounter, which can be accomplished through
the administration of a short QoL measure such as the
QOL10.
WHOQOL-BREF domain score patterns were similar to
previous findings internationally and in Norway [34, 35].
Based on strong correlations with the WHOQOL-BREF
and sensitivity to three out of five known groups [25, 36]
the QOL10, QOL5, and QOL1 tools appear to provide
Table 4 Descriptive statistics and reliability estimations of “QOL10” subscales calculated from the exploratory factor analysis
N Min Max Mean s.e.m. SD Skewness Kurtosis Cronbach’s
Subscale 1: “social QoL” 100 10 100 57.9 2.06 20.6 -.02 -.56 0.814
Subscale 2: “global QoL” 102 5 100 58.5 1.90 19.3 -.41 -.27 0.771
Descriptive statistics and reliability estimations of “QOL10’s” social and global subscales calculated from the exploratory factor analysis
QoL quality of life
Table 5 Correlations between quality of life scales, WHOQOL-BREF domains, and known groups
QOL10 QOL5 QOL1






Physical health QoL .622*** .344*** .707*** .596*** .495***
Psychological health QoL .768*** .490*** .734*** .772*** .676***
Social QoL .629*** .680*** .499*** .548*** .495***
Environment QOL .436*** .244* .452*** .382*** .501***
Overall QoL item .623*** .448*** .576*** .486*** .671***
Known groupsb
Additional chronic disease .002 .116 -.006 -.015 -.041
Clinical anxiety symptoms -.532** -.251* -.509*** -.534*** -.410***
Clinical depression symptoms -.497** -.173 -.484*** -.510*** -.425***
Physical inactivity -.369** -.094 -.392*** -.373*** -.411***
Psychiatric services utilization, past year -.119 .047 -.137 -.114 -.012
*p < 0.05; **p < 0.01, ***p < .001
aNumbers are Pearson’s correlations (r); bnumbers are point-biserial correlations (rpbc)
QoL quality of life
Convergent validity testing: Correlations between “QOL10” composite score and subscales, “QOL5”, “QOL1”, WHOQOL-BREF domains, and known groups
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valid measurements of global QoL. The lack of clear rela-
tionships to patients in the remaining two groups is not
surprising [5], and speaks to the complexity of QoL, par-
ticularly among this population with a constellation of
vulnerabilities.
Despite the variety of vulnerabilities, and strengths,
with which patients present to treatment, focus is often
predominantly given to factors deemed most relevant to
the development or amelioration of SUD [14]. A main
clinical strength of the QOL10 is therefore its social
QoL subscale and the attention it draws first to patients’
social lives, and second to patients’ own evaluations.
Utilizing subjective evaluations to measure the social
wellbeing of persons with a SUD reveals more complex
relationships between common clinical concerns and
how dis/satisfied persons are with their social lives –
perhaps an explanation as to why the social QoL sub-
scale showed no relationship to psychiatric service
utilization, additional chronic somatic disease, depres-
sion, or physical activity.
Patient evaluations of the quality of their social lives,
such as those elicited by the QOL10, are likely more
important to understanding wellbeing than objective
measures of social life, whether quantitative or qualita-
tive [37]. The social subscale of the QOL10 provides
respondents with a unique opportunity to evaluate their
relationships with their friends, family, and partners, and
to reflect on their social and sex lives, without the tool
including predetermined expectations of a certain amount
of these actors or particular roles they ought to play. This
subjectivity is a prerequisite to a good QoL measure and
the social subscale is as such a useful tool to tap into this
dimension of SUD patients’ lives.
In this validation study, the common clinical concerns
represented by the known groups included may not pre-
dict the health of respondents’ social lives, which we
know influence treatment trajectories and outcomes
[38]. This reminds us that it is both possible and worth-
while in treatment to spend attention on strengthening
the social lives of patients who might otherwise be as-
sumed to have other, more urgent needs or priorities.
Alternatively, the QOL10 might have lacked sensitivity
to two of the known groups because the burdens of
those conditions were relatively homogenous across the
sample. The validation-nature of this study, however,
limits further discussion of known group correlation, as
the study was not intended to provide a sophisticated ana-
lysis of factors influencing QoL. Further exploration of the
QOL10 should include an explicit subgroup analysis be-
tween men and women, as women report receiving less
social support than men, social support being provided
more by substance users than non-users, and providing
more support to other substance users than men provide
[39–41]. Future research should also explore clinical and
under-reported correlates of social QoL, particularly to
find out how to support patients’ social health. The
QOL10 may be improved by adding “not applicable” re-
sponses, particularly to the partner question, so that in-
applicable questions are not considered missing values.
High quality test-retest reliability assessment as well as fur-
ther psychometric testing should also be conducted [42].
Conclusion
This validation study found the “QOL10”, “QOL5”, and
“QOL1” to have sufficiently high correlations to the
WHOQOL-BREF and selected known groups to conclude
that each tool measures global QoL. The QOL10 discrimi-
nates as well as the previously validated QOL5 and QOL1.
The QOL10 should be utilized in a substance use disorder
treatment context for its two subscales capturing global
QoL and the more novel social QoL. Given the social sub-
scale’s high internal validity, we additionally suggest that it
can be a psychometrically stronger alternative to the
WHOQOL-BREF’s social relationships domain [43]. The
QOL10 measures global and social QoL constructs on par
with WHO recommendations, and practitioners inter-
ested in these constructs may find the QOL10 a shorter
and more robust tool than the WHOQOL-BREF. Our
findings support the inclusion of a distinct social domain
into QoL research [1] among this population, beyond
simply social relationships, as the WHOQOL-BREF mea-
sures. The social subscale of the QOL10 provides patients
with the rare opportunity to evaluate their social lives and
provides a reflection of these evaluations for a clinical con-
text, rather than reflecting researcher-determined prior-
ities. The single-item QOL1 and overall QOL5 tools were
also deemed valid measurements of global QoL.
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